New Eli Lilly acquisition to progress potential next-generation pain treatment
The deal will support Eli Lilly and Company to advance non-opioid medicines and expand its pain therapy pipeline.
List view / Grid view
The deal will support Eli Lilly and Company to advance non-opioid medicines and expand its pain therapy pipeline.
The EMA’s committee has granted positive opinions for ten new treatments, including medicines for oncology indications and rare diseases.
The demonstrated safety and efficacy of the aldosterone synthase inhibitor suggest its potential in helping patients with hypertension to reach their blood pressure goal, according to the data.
BioNTech’s commitment aligns with the UK Government’s Plan for Change, which involves accelerating growth of the pharmaceutical industry.
The MHRA’s consultation, announced on International Clinical Trials Day, is intended to support creation of innovative UK trials.
If approved, the oral medicine could provide a first-in-class treatment option for eligible individuals with the chronic 24-hour disease.
The unique mechanism of action of efimosfermin supports its potential as a new standard-of-care in liver disease.
14 May 2025 | By
The use of AI technology in unifying clinical data across systems for making clinical trials more effective, safer and more efficient.
The novel cell therapy utilises a shortened manufacturing process compared to standard production timelines, offering potential for enhanced therapeutic capability.
The biologic delivered sustained remission in adults with the inflammatory bowel disease (IBD) over the two-year study, results show.
With clinical data showing the gene therapy can address large and challenging chronic wounds, the FDA’s decision will help improve quality of life for dystrophic epidermolysis bullosa (DEB) patients.
The merger deal between Novartis AG and Regulus Therapeutics is expected to push forward development of a potential first-in-class kidney disease drug.
The partnership between Eli Lilly and Company and Creyon Bio will focus on producing safer, more effective RNA-targeted oligonucleotide therapies with the use of AI technology.
The collaboration between Boehringer Ingelheim and Tessellate Bio seeks to address availability of targeted medicines for a cancer type shown to be difficult to treat.
The findings suggest that the biologic treatment could improve short-term outcomes for patients with lupus nephritis.